Corrine Savill
CIK: 0001837524
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
CGEM
Cullinan Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
About Savill Corrine
Savill Corrine (SEC CIK 0001837524) files insider reports with the SEC as Chief Business Officer of Cullinan Therapeutics, Inc. (CGEM).
Signal8 holds 2 ownership filings by Savill Corrine, all Form 4s, filed between Feb 21, 2025 and Feb 19, 2026. Those filings report 2 transactions, from Feb 19, 2025 to Feb 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Savill Corrine's filings is in CAMBRIDGE, MA.
Recent filings by Savill Corrine
Other insiders filing for Cullinan Therapeutics, Inc. (CGEM)
- Michaelson Jennifer, Chief Scientific Officer
- SUMER JACQUELYN L, Chief Legal Officer
- Fenton Mary Kay, Chief Financial Officer
- Rosenberg Anthony, Director
- Meek David D., Director
- Webster Stephen W, Director